绥美凯适用于哪些病症？

(Dolutea Paramide Tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a body weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Dolutegravir is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014. On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation dolutegravir (Triumeq), which is based on the new generation integrase inhibitor dolutegravir (DTG) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

TRIUMEQ is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40 kg). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Once infected with AIDS, it will lead to a rapid decline in immunity. When immunity declines, it is easy to get sick and other symptoms will appear. When the HIV virus enters the human body, it will not make the human body feel abnormal very quickly, so the disease needs to be treated. There are many hazards. Due to the decline of the body's resistance, various infections will occur, such as herpes zoster, oral mold infection, tuberculosis, enteritis, pneumonia, encephalitis caused by special pathogenic microorganisms, severe infections caused by Candida, Pneumocystis jiroveci and other pathogens. In the later stage, malignant tumors often occur, and long-term consumption occurs, leading to systemic failure and death. The advent of AIDS has helped patients alleviate their pain to a certain extent, delayed the progression of the disease, and brought hope to AIDS patients.